This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $229.64, moving -0.53% from the previous trading session.
Danaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $230.87, signifying a -1.7% move from its prior day's close.
Here's Why Danaher (DHR) Fell More Than Broader Market
by Zacks Equity Research
The latest trading day saw Danaher (DHR) settling at $230.81, representing a -1.7% change from its previous close.
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO
Danaher (DHR) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $234.79, signifying a +1.49% move from its prior day's close.
Danaher (DHR) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $232.86, moving +0.63% from the previous trading session.
Reasons to Retain Danaher (DHR) Stock in Your Portfolio Now
by Zacks Equity Research
Strength in the Life Sciences segment and accretive acquisition bode well for Danaher (DHR). The company's measures to reward its shareholders are encouraging.
Danaher (DHR) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $226.45, moving -0.34% from the previous trading session.
Danaher (DHR) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $221.35, signifying a +1.77% move from its prior day's close.
Danaher (DHR) Acquires Abcam to Boost Life Sciences Segment
by Zacks Equity Research
Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
Danaher (DHR) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Danaher (DHR) settling at $219.44, representing a -1.21% change from its previous close.
Danaher (DHR) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $222.52, signifying a +1.72% move from its prior day's close.
Danaher (DHR) Up 14.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO
Tools & Outdoor Weakness Hurt Stanley Black's (SWK) Sales in Q3
by Zacks Equity Research
Weakness in the Tools & Outdoor unit due to lower consumer outdoor and DIY market demand weighs on Stanley Black's (SWK) top line in Q3. However, lower costs drive the bottom line.
Honeywell (HON) Beats on Q3 Earnings & Revenues, Revises View
by Zacks Equity Research
Honeywell's (HON) Q3 results benefit from growth in commercial aviation, defense and space, and process solutions. The company revises its 2023 guidance.
Danaher's (DHR) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
While Danaher (DHR) surpasses Q3 earnings and revenue estimates, the company's performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Life Sciences segment.
Here's What Key Metrics Tell Us About Danaher (DHR) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher (DHR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 10.38% and 3.95%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Danaher (DHR) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $205.83, signifying a -0.71% move from its prior day's close.
Why the Market Dipped But Danaher (DHR) Gained Today
by Zacks Equity Research
In the most recent trading session, Danaher (DHR) closed at $207.30, indicating a +1.22% shift from the previous trading day.
Honeywell International Inc. (HON) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Honeywell International Inc. (HON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Diagnostic Unit Weakness Mar Danaher's (DHR) Q3 Earnings?
by Zacks Equity Research
Danaher's (DHR) Q3 results are likely to be hurt by weakness in the Biotechnology and Diagnostics segments due to a decrease in the sale of COVID-related products.
Danaher (DHR) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
Danaher (DHR) reachead $209.43 at the closing of the latest trading day, reflecting a -0.03% change compared to its last close.